Brief: NewAmsterdam Pharma Announces Positive Topline Data From Pivotal Phase 3 Tandem Clinical Trial

NewAmsterdam Pharma

20/11/2024 12:18

Nov 20 (Reuters) - NewAmsterdam Pharma Company NV
 KH6.F :
    * NEWAMSTERDAM PHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM
PIVOTAL
PHASE 3 TANDEM CLINICAL TRIAL EVALUATING THE FIXED-DOSE
COMBINATION OF OBICETRAPIB 10 MG AND EZETIMIBE 10 MG IN PATIENTS
WITH ASCVD OR ASCVD RISK FACTORS AND/OR HEFH
    * NEWAMSTERDAM PHARMA COMPANY NV - PHASE 3 TANDEM TRIAL
ACHIEVES
ALL CO-PRIMARY ENDPOINTS
    * NEWAMSTERDAM PHARMA COMPANY NV - DATA SUPPORTS GLOBAL
REGULATORY
FILINGS FOR FIXED-DOSE COMBINATION
    * NEWAMSTERDAM PHARMA COMPANY NV - FIXED-DOSE COMBINATION
WELL
TOLERATED WITH SAFETY RESULTS IN LINE WITH PRIOR STUDIES
    * NEWAMSTERDAM PHARMA COMPANY NV: TANDEM TRIAL MET ALL
CO-PRIMARY
ENDPOINTS

Source text:  ID:nGNXbl6Y7n 
Further company coverage:  KH6.F 

 ((Reuters.Briefs@thomsonreuters.com;))